Retinal tissue may degenerate for a number of reasons. Among them are: artery or vein occlusion, diabetic retinopathy, R.L.F./R.O.P. or disease (usually hereditary). Retinitis pigmentosa, retinoschisis, lattic degeneration, and macular degeneration are characterized by progressive types of retinal degeneration.
In the retina of the eye, rod and cone cells turn light into electrical signals, the first step toward human vision.
Researchers with funding from Fight for Sight have demonstrated that a new drug treatment for cystic fibrosis and Duchenne muscular dystrophy can override a genetic fault that causes choroideremia – a severe blinding disorder.
Columbia University Medical Center researchers have demonstrated that vision loss associated with a form of retinitis pigmentosa (RP) can be slowed dramatically by reprogramming the metabolism of photoreceptors, or light sensors, in the retina.
Diseases of the central nervous system (CNS) may manifest as pathological changes in the retina of the eye.
Researchers have demonstrated the ability to deliver a fully functional copy of the CLN3 gene to stem cells of patients with juvenile NCL, an inherited neurodegenerative disease in which a mutation in the CLN3 gene causes early-onset severe central vision loss.
A $1.9 million grant to Indiana University from the National Institutes of Health's National Eye Institute will advance basic research on the eye with applications to blindness caused by genetic disorders and aging.
Ciliopathies are diseases that affect the cilia, sensory organelles that most mammalian cells possess and which play a critical role in many biological functions.
A large screening programme has identified several genes associated with age-related conditions including hearing loss, retinal degeneration and osteoarthritis.
Combinations of Food and Drug Administration-approved drugs protect against the loss of cells required for vision in a mouse model of blinding retinal diseases.
A team led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of LSU Health New Orleans' Neuroscience Center of Excellence, has developed neuroprotective compounds that may prevent the development of epilepsy.
A pain medicine that potently activates a receptor vital to a healthy retina appears to help preserve vision in a model of severe retinal degeneration, scientists report.
The National Eye Institute (NEI), part of NIH, is participating in the Inaugural Press Conference from the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2016), the largest gathering of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75 countries.
Scientists at Oregon Health & Science University's Casey Eye Institute and Baylor College of Medicine's Cullen Eye Institute published findings from a two-year Phase I clinical trial in the journal Ophthalmology, which showed that children had the greatest benefit from gene therapy for treatment of Leber congenital amaurosis (LCA) or severe early childhood onset retinal degeneration (SECORD).
A Massachusetts General Hospital investigator has found that increased expression of the angiogenic factor VEGF-A promotes three common aging-related eye conditions - both versions of age-related macular degeneration (AMD) and also cataracts - in an animal model.
A new technique that has the potential to treat inherited diseases by removing genetic defects has been shown for the first time to hinder retinal degeneration in rats with a type of inherited blindness, according to a Cedars-Sinai study.
The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) - the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis.
The American Academy of Ophthalmology will pay tribute to outstanding eye physicians and surgeons who have made significant achievements in various areas of the profession. These range from scientific innovation and humanitarian service to education and advocacy. The honorees will be recognized AAO 2015, the Academy's 119th annual meeting in Las Vegas.
Scientists have good news for patients who suffer from currently untreatable dry age-related macular degeneration (dry AMD). In a new study, researchers identified a potential target for future therapies to slow the progression of the blinding condition. Published in Investigative Ophthalmology & Visual Science, the findings indicate that treatments currently used for other conditions could also work for dry AMD.
The animal brain is so complex, it would take a supercomputer and vast amounts of data to create a detailed 3-D model of the billions of neurons that power it.
A collaboration between scientists in the UK and the USA has shown that gene therapy can give life-long protection to the light-sensitive photoreceptor cells responsible for colour vision in a mouse model of the most common inherited eye disorder.